All three major indices are trading up today with the

Dow Jones Industrial Average

(

^DJI

) trading up 44 points (0.3%) at 17,560 as of Monday, March 28, 2016, 1:00 PM ET. The NYSE advances/declines ratio sits at 1,693 issues advancing vs. 1,250 declining with 166 unchanged.

The Drugs industry currently sits down 0.7% versus the S&P 500, which is up 0.2%. On the negative front, top decliners within the industry include

Ionis Pharmaceuticals

(

IONS

), down 7.3%,

Alkermes

(

ALKS

), down 3.9%,

Endo International

(

ENDP

), down 3.5%,

Perrigo

(

PRGO

), down 2.8% and

Mylan

(

MYL

), down 1.8%.

TheStreet would like to highlight 3 stocks pushing the industry higher today:

3.

ACADIA Pharmaceuticals

(

ACAD

) is one of the companies pushing the Drugs industry higher today. As of noon trading, ACADIA Pharmaceuticals is up $4.30 (21.2%) to $24.61 on heavy volume. Thus far, 8.8 million shares of ACADIA Pharmaceuticals exchanged hands as compared to its average daily volume of 2.3 million shares. The stock has ranged in price between $23.55-$25.49 after having opened the day at $24.47 as compared to the previous trading day's close of $20.31.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. ACADIA Pharmaceuticals has a market cap of $2.3 billion and is part of the health care sector. Shares are down 43.0% year-to-date as of the close of trading on Thursday. Currently there are 7 analysts who rate ACADIA Pharmaceuticals a buy, no analysts rate it a sell, and none rate it a hold.

TheStreet Ratings rates

ACADIA Pharmaceuticals

as a

sell

. The company's weaknesses can be seen in multiple areas, such as its feeble growth in its earnings per share, deteriorating net income, disappointing return on equity, weak operating cash flow and generally disappointing historical performance in the stock itself. Get the full

ACADIA Pharmaceuticals Ratings Report

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

2. As of noon trading,

Alexion Pharmaceuticals

(

ALXN

) is up $1.74 (1.3%) to $134.93 on light volume. Thus far, 573,333 shares of Alexion Pharmaceuticals exchanged hands as compared to its average daily volume of 1.9 million shares. The stock has ranged in price between $131.93-$134.98 after having opened the day at $133.95 as compared to the previous trading day's close of $133.19.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Alexion Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes life-transforming therapeutic products. Alexion Pharmaceuticals has a market cap of $30.0 billion and is part of the health care sector. Shares are down 30.2% year-to-date as of the close of trading on Thursday. Currently there are 14 analysts who rate Alexion Pharmaceuticals a buy, no analysts rate it a sell, and 4 rate it a hold.

TheStreet Ratings rates

Alexion Pharmaceuticals

as a

hold

. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures and expanding profit margins. However, as a counter to these strengths, we also find weaknesses including a generally disappointing performance in the stock itself, deteriorating net income and disappointing return on equity. Get the full

Alexion Pharmaceuticals Ratings Report

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

1. As of noon trading,

Gilead

(

GILD

) is up $2.06 (2.3%) to $93.38 on average volume. Thus far, 5.0 million shares of Gilead exchanged hands as compared to its average daily volume of 12.9 million shares. The stock has ranged in price between $91.94-$94.31 after having opened the day at $92.00 as compared to the previous trading day's close of $91.32.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Gilead Sciences, Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in areas of unmet medical needs in North America, South America, Europe, and the Asia-Pacific. Gilead has a market cap of $124.8 billion and is part of the health care sector. Shares are down 9.8% year-to-date as of the close of trading on Thursday. Currently there are 11 analysts who rate Gilead a buy, no analysts rate it a sell, and 5 rate it a hold.

TheStreet Ratings rates

Gilead

as a

buy

. The company's strengths can be seen in multiple areas, such as its robust revenue growth, notable return on equity, attractive valuation levels, expanding profit margins and good cash flow from operations. We feel its strengths outweigh the fact that the company has had lackluster performance in the stock itself. Get the full

Gilead Ratings Report

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

If you are interested in one of these 3 stocks, ETFs may be of interest. Investors who are bullish on the drugs industry could consider

SPDR S&P Pharmaceuticals ETF

(

XPH

) while those bearish on the drugs industry could consider

ProShares UltraShort Nasdaq Biotech

(

BIS

).